AstraZeneca plc AZNmissed the Zacks Consensus Estimate for both earnings and sales in the first quarter of 2018 hit by declining sales of its cholesterol drug, Crestor. The Swiss pharma giant maintained its previously issued outlook for 2018. The stock declined more than 2% in pre-market trading on Friday.
AstraZeneca's (AZN) Q1 Earnings & Sales Miss, Stock Down
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться